- Charles T. Campbell PhD – University of Washington
- Leroy Hood – Institute for Systems Biology
- Joshua LaBaer – Biodesign Institute at Arizona State University
- James Richey – Richey and Associates
- Ulf Jönsson – Retired
- Craig Beeson – Medical University of South Carolina
Charles T. Campbell is the Lloyd E. and Florence M. West Professor of Chemistry at the University of Washington. He is an elected Fellow of both the American Association for the Advancement of Science and of the American Chemical Society. He has received the Arthur W. Adamson Award of American Chemical Society (ACS) and its Award for Colloid or Surface Chemistry, the Gerhard Ertl Lecture Award, the Ipatieff Lectureship at Northwestern University, an Alexander von Humboldt Research Award in Germany, a Dreyfus Foundation Teacher / Scholar Award, the John Yarwood Award of the British Vacuum Council and the St. John s College Visiting Scholarship at Cambridge University. He served as Editor-in-Chief of Surface Science for over a decade, and as Chairman, Chairman-Elect, Vice-Chairman and Treasurer of the Colloid and Surface Chemistry Division of the American Chemical Society. He was the founding Co-Director and Director of the University of Washington's Center for NanoTechnology, and helped develop the USA s first PhD program in Nanotechnology there. He is the author of over 260 publications on surface chemistry, catalysis and biosensing, with a Hirsch h-index of 62 and more than 800 citations each year for the past four years. He received his B.S. in Chemical Engineering (1975) and his Ph.D. in Physical Chemistry under J. M. White (1979) from the University of Texas at Austin. He did postdoctoral research in Germany with Gerhard Ertl (2007 Nobel Prize Winner).
Dr. Hood is a pioneer in the systems approach to biology and medicine. His research has focused on the study of molecular immunology, biotechnology and genomics. Dr. Hood's professional career began at Caltech, where he and his colleagues developed the DNA gene sequencer and synthesizer and the protein synthesizer and sequencer––four instruments that paved the way for the successful mapping of the human genome. A pillar in the biotechnology field, Dr. Hood has played a role in founding more than fourteen biotechnology companies, including Amgen, Applied Biosystems, Darwin, The Accelerator and Integrated Diagnostics. He is a member of the National Academy of Sciences, the National Academy of Engineering, and the Institute of Medicine. Of the 6,000+ scientists world-wide who belong to one or more of these academies, Dr. Hood is one of only fifteen people accepted to all three. He is also a member of the American Philosophical Society and a Fellow of the American Academy of Arts and Sciences. His work has been widely published, and he has coauthored numerous textbooks in biochemistry, immunology, molecular biology and genetics, as well as a popular book on the human genome project, The Code of Codes. He is the recipient of numerous awards, including the Lasker Award for Studies of Immune Diversity, the Kyoto Prize in advanced technology, the Heinz Award for pioneering work in Systems Biology, and most recently, the coveted NAE 2011 Fritz J. and Delores H. Russ Prize for automating DNA sequencing that revolutionized biomedicine and forensic science. In addition to having received 17 honorary degrees from prestigious universities in the US and abroad, Dr. Hood has published more than 700 peer reviewed articles and currently holds 36 patents.
Joshua LaBaer, MD, PhD, is the newly appointed director of the Virginia G. Piper Center for Personalized Diagnostics with in the Biodesign Institute at Arizona State University. He was also the founder and Director of the Institute of Proteomics at Harvard Medical School, and is a board certified oncologist in Massachusetts. He attended the University of California at Berkeley as an undergraduate and completed medical school and graduate school at the University of California, San Francisco, where he studied steroid regulation of DNA transcription and protein-DNA interactions.
He completed his clinical studies at the Brigham and Women’s Hospital and a clinical fellowship in Oncology at the Dana-Farber Cancer Institute in Boston. He also pursued research interests at the Massachusetts General Hospital in Boston in the areas of breast cancer, mammalian cell cycle regulation and cell cycle checkpoint genes.
Dr. LaBaer is the inventor of a new protein array technology called Nucleic Acid Programmable Protein Arrays (NAPPA). The NAPPA technology, first published in the July 2004 issue of the journal Science, provides a simple, cost-effective way to produce, as a single element of a microarray, freshly synthesized protein corresponding to any gene of known sequence.
He currently holds an academic appointment through the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School. The author of numerous publications, Dr. LaBaer is also an associate editor of the Journal of Proteome Research, a member of the Scientific Advisory Committee for the Proteome Society and a founding member of the Human Proteome Organization.
Mr. Richey is a co-founder, President and CEO of Auguron, a protein array company spun out of Harvard Medical School. Mr. Richey has been involved with a variety of biotech tool companies in varying and increasing levels of responsibility for the last 30 years. Companies in which he has held the position of Vice President or above include: Pharmacia, Biacore, PerSeptive, Applied Biosystems, LJL biosystems, Molecular Devices, and DiscoveRx. For the last 5 years Mr. Richey has run a successful consulting practice devoted to supporting the tool company space.
Dr. Ulf Jönsson has a distinguished career spanning more than 20 years as an executive in the life science supply industry. Most notably, he was one of the three founders of Biacore AB, which began in 1984 as a research department within Pharmacia Fine Chemicals. In 1987 this research was transferred into a wholly owned subsidiary, Pharmacia Biosensor AB, which became Biacore AB in 1996. Biacore was subsequently acquired by GE Healthcare in 2006. Dr. Jönsson was CEO at Biacore from 2000 until 2004. He holds a Ph.D. in applied physics from the University of Linköping in Sweden.
Craig Beeson comes from Southern California where he obtained his Ph.D. in synthetic and physical organic chemistry from the University of California at Irvine. He continued his studies with postdoctoral research under the supervision of Harden McConnell at Stanford University where he studied biophysics and immunology. He started his academic career at the University of Washington in Seattle in the Departments of Chemistry, Biochemistry, and Immunology. He was recruited to the Department of Pharmaceutical and Biomedical Sciences at the Medical University of South Carolina in 2002 where he remains today. The focus of his research is in the areas of structure-based drug design, analyses of signaling networks, and the regulation of cellular energy metabolism. He is the director of the MUSC Metabolomics Core and the MUSC Drug Design and Synthesis Core.